Skip to content

Use of pearl Millets in newly diagnosed type 2 diabetes patients for improving insulin sensitivity and glycemic variability

Effect of Pearl Millet on glycaemic variability and insulin sensitivity in newly diagnosed type 2 diabetes mellitus - an open label parallel randomized controlled trial - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/12/099084
Enrollment
212
Registered
2025-12-15
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E118- Type 2 diabetes mellitus with unspecified complications

Interventions

Intervention1: Millet group: Intervention group in addition to standard diet compostion and 30 percent calories restriction along with physical activities will have at least one meal composed of pearl

Sponsors

Council of Science and Technology UP
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age 18 to 60 years Diagnosed to have type 2 diabetes. Type 2 diabetes mellitus will be defined by glycosylated hemoglobin more than 6.5 percent or fasting plasma glucose more than 126 mg per dL or random blood glucose more than 200 mg per dL and diabetes not requiring any oral hypoglycemic agents or insulin for glycemic control

Exclusion criteria

Exclusion criteria: History of allergy to millets Secondary diabetes Type 1 Diabetes Gestational diabetes. Use of nutritional supplements Pregnant or lactating women Known severe chronic liver disease- patients with liver cirrhosis (hepatitis B virus, hepatitis C virus, autoimmune hepatitis, or alcohol related liver disease Pharmacological treatment with immunosuppressants Patients who were on anti obesity drugs corticosteroids, or anti psychotics Acute infections malignancy Any condition that hinders compliance to the intervention

Design outcomes

Primary

MeasureTime frame
1.Insulin resistance by HOMA IR at 12 weeks in two groups 2.Glycemic variability ( TIR) by continuous glucose monitoring over 14 days Timepoint: 1.Insulin resistance by HOMA IR at 12 weeks in two groups 2.Glycemic variability ( TIR) by continuous glucose monitoring over 14 days

Secondary

MeasureTime frame
1. Markers of inflammation( HsCRP, Tnf Alpha, IL6)-Timepoint: at 12 weeks in two groups

Countries

India

Contacts

Public ContactDR RITU KAROLI

Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow

ritu.karoli@rediffmail.com9415547894

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026